News from isis pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 15, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals Earns $2M from the Advancement of ISIS-SMN Rx in Children with Spinal Muscular Atrophy

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $2 million milestone payment from Biogen Idec related to the...

Aug 04, 2014, 08:30 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Reports Financial Results and Highlights for Second Quarter 2014

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today reported pro forma net operating income of $1.1 million and a pro forma net operating loss...

Aug 01, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the initiation of a pivotal Phase 3 study evaluating ISIS-SMNRx in infants with...

Jul 28, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Isis Pharmaceuticals' Second Quarter 2014 Financial...

Jul 17, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-APO(a) Rx in Patients with High Lp(a)

 Isis Pharmaceuticals, Inc.  (NASDAQ: ISIS) announced the initiation of a Phase 2 study evaluating ISIS-APO(a)Rx in patients with high...

Jul 16, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals Earns $1 Million from GSK for Advancing ISIS-TTR Rx

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related...

Jul 02, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals Earns $1 Million From GSK for Advancing Hepatitis B Virus Program

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million payment from GlaxoSmithKline (GSK) related to the...

Jun 24, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals Earns $1 Million From GSK for Advancing ISIS-TTR Rx

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $1 million milestone payment from GlaxoSmithKline (GSK) related to...

Jun 17, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals Earns $10 Million Milestone Payment from Biogen Idec

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today it has earned a $10 million milestone payment from Biogen Idec associated with the...

Jun 16, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals Reports Final Phase 2 Data on ISIS-GCGR RX Showing Significant Reduction in HbA1c in Patients with Type 2 Diabetes

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the final results from its Phase 2 study of ISIS-GCGRRx in patients with type 2...

Jun 12, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals to Present at the 2014 Wells Fargo Healthcare Conference

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company...

Jun 11, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals to Host Investor Event to Discuss ISIS-GCGR Rx Phase 2 Data Presented at the 2014 ADA Scientific Sessions

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host an investor event and a live webcast on Monday, June 16, 2014 at...

Jun 10, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals Earns $15 Million from AstraZeneca for Initiation of Phase 1 Study of ISIS-AR Rx

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that AstraZeneca has initiated a Phase 1 clinical study of ISIS-ARRx in patients with...

Jun 09, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-DMPK Rx to Treat Myotonic Dystrophy Type 1

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 study for ISIS-DMPKRx.  Isis earned a $14...

Jun 04, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals to Present at The Goldman Sachs 35th Annual Global Healthcare Conference

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company...

Jun 03, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals to Present a General Corporate Update at its 2014 Annual Meeting of Stockholders and Open House

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a general corporate...

May 22, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx in the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive top-line data from a Phase 2 comparator-controlled study evaluating the...

May 20, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-PKK Rx

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it initiated a Phase 1 clinical study of ISIS-PKKRx.  ISIS-PKKRx is an...

May 16, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Webcast Alert: Isis Pharmaceuticals Announces its R&D Day Presentation

 Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Isis Pharmaceuticals' R&D Day...

May 15, 2014, 07:00 ET
Isis Pharmaceuticals, Inc.  (PRNewsFoto/Isis Pharmaceuticals, Inc.)

Isis Pharmaceuticals Earns $3.0 Million from GSK

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $3.0 million milestone payment from GlaxoSmithKline (GSK) related to...